FERN, your post is one that may encompass how I feel and what I've been suggesting in recent posts.
Specifically, ACTC hope is to be onto something potentially significantly larger in scope than their eye disease focus, and that may be beyond our current management's ability to put it's arms around, or just too early in our clinical testing success to attract and define any serious longterm relationships with other parties.
Out of fairness to to management, relationship are very rare at this early stage in a company's clinical development. We will never know in all probability, but I hope it's because we investors would like too much too soon in this process, especially given some of the 'baggage' we carry and we just need to continue to be patient.
Some of the complicating variables / 'baggage', from my limited perspective are firstly; probably too soon in clinical development/testing matters for partnerships; cleaning up the financial debt sheet through resolution on remaining outstanding global settlement litigation and the current SEC investigation; the true status and board planning on a RS and uplisting and our ability to meet the real requirements for that.
ACTC is a potential investing gem in the making. The question for me remains, assuming continued clinical success, are our ceo and management team experienced enough and up to the challenge?
As a long term investor, waiting and waiting for this to develop and break out, I'm always probing, hence many of my critical comments, but just one thought/example to share .... our stock recently hit a high of 09. Why didn't we seize that opportunity to announce the RS and uplisting. The potential numbers sure looked favorable to me, especially coupled with the approval and start of the 100,000 stem cell injections?
AI
Market Data 
Markets 
